Kathryn Packman
10Patents
3h-index
38Co-inventors
56Inventor score
Filing activity: Aug 10, 2011 → Nov 18, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9486445B2 | Combination therapy for proliferative disorders | Human Necessities | 10 | Active |
| US9926379B2 | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 | Chemistry; Metallurgy | 10 | Active |
| US8709419B2 | Combination therapy | Chemistry; Metallurgy | 3 | Active |
| US9216170B2 | Combination therapy for proliferative disorders | Human Necessities | 3 | Active |
| US11214622B2 | Antibodies specific for DR5 and methods of use | Chemistry; Metallurgy | 2 | Active |
| US8741889B2 | Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor | Chemistry; Metallurgy | 1 | Active |
| US9956243B2 | Combination treatment for acute myeloid leukemia (AML) | Human Necessities | 1 | Active |
| US11571437B2 | Methods of treating cancer using PRMT5 inhibitors | Human Necessities | 0 | Active |
| US11738003B2 | Method for administration | Human Necessities | 0 | Active |
| US9295669B2 | Combination therapy for proliferative disorders | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.